+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 3
Age: 12Years - 80Years
All Genders
ID04918173

Open-Label Study Evaluating Atenativ for Surgery or Delivery in Patients With Congenital Antithrombin Deficiency

Led by Octapharma · Updated on 2026-09-28

38

Participants Needed

30

Research Sites

N/A

Total Duration

AI-Summary

What This Trial Is About

This research aims to evaluate the occurrence of blood clots, specifically thrombotic and thromboembolic events, in patients with congenital antithrombin deficiency who are undergoing surgery or childbirth. The study focuses on patients receiving Atenativ, an antithrombin concentrate, to understand its effects during these high-risk procedures. It is a Phase 3, open-label, uncontrolled study sponsored by Octapharma to assess efficacy, safety, and pharmacokinetics. Participants first enter a pharmacokinetic phase where they receive a single intravenous infusion of Atenativ at a dose of 60 IUkg to analyze how the drug behaves in the body. Following this, in the treatment phase, patients receive a single intravenous loading dose of Atenativ followed by maintenance doses every 24 hours. Surgical patients receive treatment for about 2 to 7 days, while pregnant participants receive treatment for approximately 5 days around the time of delivery or cesarean section. Throughout the study, participants will be monitored for blood clot events up to 30 days after starting treatment. Blood tests will measure various coagulation parameters and drug levels at multiple time points up to 14 days after the initial infusion. Safety and tolerability will also be assessed by tracking adverse events during this period. The total participation extends through the treatment and follow-up phases to ensure comprehensive evaluation of outcomes.

CONDITIONS

Brief Title

Efficacy of Atenativ in Patients With Congenital Antithrombin Deficiency Undergoing Surgery or Delivery

Research Team

S

Sigurd Knaub

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here